Bloomberg Stock Movers

2026-06-09 · Hosted by — · Bloomberg / iHeartMedia

Executive Summary

This Bloomberg Stock Movers report led with Nuvalent surging ~39% pre-market on news that GSK agreed to buy the Cambridge biotech for $124 a share to rebuild its cancer pipeline. Apple slipped ~0.3% as investors stayed unconvinced by the WWDC “Siri AI” reveal, drawing sharply mixed analyst reviews. Neocloud operator Applied Digital jumped nearly 11% on a 15-year, $5.2 billion hyperscaler lease, and Vail Resorts fell ~4% after cutting full-year guidance on poor snowfall.

Key Stories & Changes

1. Nuvalent / GSK Merger

  • Nuvalent (NUVL) up ~39% pre-market; GSK agreed to acquire it for $124/share

  • GSK is rebuilding its cancer pipeline after slow growth since returning to oncology in 2019

  • Nuvalent has two medicines in late-stage trials; FDA decisions on both due this year, and GSK says they could be blockbusters if approved

2. Apple WWDC Skepticism

  • Apple (AAPL) down ~0.3% pre-market; investors “still not convinced” after the WWDC keynote

  • New overhauled assistant branded Siri AI is the centerpiece of new operating systems

  • Mixed analyst reviews: Wedbush bullish (“unveiled an AI strategy that will unleash the true monetization opportunity”); Vital Knowledge called the keynote “a disappointment”

  • Key issue is timelines — a long-term strategy Wall Street is still trying to price

3. Applied Digital Hyperscaler Deal

  • Applied Digital (APLD) up nearly 11% pre-market; neocloud (specialized AI infrastructure) operator

  • Signed a 15-year lease with a US-based hyperscaler for 210 megawatts at its Delta 4.2 campus

  • $5.2 billion in base-term revenue, up to nearly $13 billion over a 30-year term

  • Notable: Delta 4.2 isn’t expected to open until ~2028, signaling strong forward demand

  • Dragged peers higher: CoreWeave +3%, Nebius +4% pre-market

4. Vail Resorts Earnings

  • Vail Resorts (MTN) down ~4% pre-market after cutting full-year net income guidance

  • Sees 2026 EBITDA down 14% from its original September forecast on “historically challenging weather”

  • Rocky Mountain resorts saw a 24% drop in visits

Pre-Market Movers Summary

  • NUVL: Nuvalent — +~39% — GSK to acquire at $124/share to rebuild cancer pipeline

  • APLD: Applied Digital — +~11% — 15-yr, $5.2B hyperscaler lease at Delta 4.2

  • AAPL: Apple — -~0.3% — Investors unconvinced by Siri AI; mixed reviews

  • MTN: Vail Resorts — -~4% — Guidance cut on poor snowfall, visits down 24%

  • CRWV: CoreWeave — +3% — Lifted in sympathy with Applied Digital deal

  • NBIS: Nebius — +4% — Lifted in sympathy with Applied Digital deal

1. Pharma M&A to Rebuild Pipelines

GSK’s $124/share bid for Nuvalent shows large pharma using acquisitions to re-enter and expand in oncology, paying a steep premium for late-stage assets with potential blockbuster approvals due this year.

2. Forward-Booked AI Infrastructure Demand

Applied Digital’s 15-year lease for a campus that won’t open until 2028 — and the sympathetic moves in CoreWeave and Nebius — underscores how hyperscalers are locking up specialized AI compute years in advance, a durable demand signal for neocloud operators.

3. Apple’s AI Reveal Splits Wall Street

The polarized Wedbush-vs-Vital-Knowledge reaction captures genuine uncertainty over Apple’s Siri AI strategy, with the debate centered on execution timelines rather than the vision itself. —-

Sentiment Analysis

Overall Market Sentiment: Mixed

A merger-driven biotech pop and a strong AI-infrastructure deal lifted spirits, offset by lingering Apple skepticism and a weather-hit Vail.

Risk Factors Highlighted

FDA approval risk: Nuvalent’s blockbuster case depends on two pending FDA decisions this year.

Apple timeline uncertainty: Siri AI is a long-term strategy whose payoff timing is unclear to Wall Street.

Forward-demand execution: Applied Digital’s revenue hinges on a Delta 4.2 campus not opening until ~2028.

Weather/operational risk: Vail’s 24% visit drop shows how poor snowfall can force guidance cuts.

Analyst dispersion: Sharply divided Apple reviews signal elevated uncertainty around the AI thesis.

This episode was covered in today’s The Market Signal — 2026-06-09, a cross-source synthesis of multiple podcast reports.

Keep Reading